Drug for insulin resistance prevents stroke and heart attack in high-risk patients

We'll see how long this takes to be disseminated. I'm guessing 50 years.
http://www.mdlinx.com/internal-medicine/top-medical-news/article/2016/02/19/5

Yale School of Medicine News

A drug designed to treat insulin resistance reduced the risk of stroke and heart attack in non–diabetic patients who had experienced a recent stroke or transient ischemic attack (TIA), a new study shows. The findings, presented at the International Stroke Conference on Feb. 17, demonstrate a promising new approach to preventive care after stroke, said the researchers. The Insulin Resistance After Stroke (IRIS) Trial is the largest stroke trial to date funded by the National Institutes of Health. Researchers from seven countries enrolled 3,876 non–diabetic patients with a recent ischemic stroke or TIA who were insulin resistant. They gave participants either pioglitazone or a placebo for nearly five years. This drug is usually used in patients with type 2 diabetes to reduce blood–sugar levels. The researchers found that pioglitazone reduced the absolute risk of recurrent stroke and heart attack by 2.8% and the relative risk by 24% when added to standard preventive care. In addition to preventing stroke and heart attack, pioglitazone cut in half the risk of diabetes and reduced blood sugar, systemic inflammation, triglyceride levels, and systolic blood pressure. Pioglitazone had no significant effect on LDL cholesterol but increased the concentration of HDL cholesterol.